VLS Valneva SE

Valneva SE Shareholding Declaration - March 2025

Valneva SE Shareholding Declaration - March 2025

VALNEVA

Declaration of shares and voting rights

March 31, 2025

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment B

Declaration date: April 3, 2025

Number of shares

composing the share capital of Valneva
Total number of voting rights including suspended voting rights* Description of the change Date on which this change was recognized Total number of voting rights excluding suspended voting rights**
 162,521,524



 ordinary shares with a par value of €0.15 each
178,409,478 Double voting rights granted on 1,456 ordinary shares Between March 2 & March 28, 2025 178,285,156

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
03/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

 PRESS RELEASE

Valneva Provides Update on Recommendation for Use of Its Chikungunya V...

Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities Saint Herblain (France), April 26, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that France’s national public health agency, the Haute Autorité de Santé (HAS), has updated its recommendation for use of Valneva’s single-dose chikungunya vaccine IXCHIQ® for the prevention of disease caused by the chikungunya virus (CHIKV) following reports of serious adverse events (SAEs) in elderly people with comorbidities during the ongoing vaccination campaign in ...

 PRESS RELEASE

Valneva fait un point sur la recommandation d’utilisation de son vacci...

Valneva fait un point sur la recommandation d’utilisation de son vaccin contre le chikungunya par les autorités françaises Saint Herblain (France), le 26 avril 2025 – (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que l’autorité publique de santé en France, la Haute Autorité de Santé (HAS), a mis à jour sa recommandation concernant l'utilisation du vaccin à dose unique de Valneva, IXCHIQ®, pour la prévention de la maladie causée par le virus du chikungunya (CHIKV) suite à une notification d'effets indésirables graves chez des personnes â...

 PRESS RELEASE

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vac...

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers Saint Herblain (France), April 18, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that during its regular meeting on April 16, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) updated its recommendation for use of Valneva’s single-dose chikungunya vaccine IXCHIQ® for the prevention of disease caused by the chikungunya virus (CHIKV). ACIP maintained its current recommendation for IXCHI...

 PRESS RELEASE

Valneva fait le point sur la recommandation de l'ACIP pour les voyageu...

Valneva fait le point sur la recommandation de l'ACIP pour les voyageurs américains concernant son vaccin IXCHIQ® contre le chikungunya Saint-Herblain (France), le 18 avril 2025 – (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que lors de sa réunion ordinaire du 16 avril 2025, le comité consultatif américain sur les pratiques d'immunisation (ACIP) des centres de contrôle et de prévention des maladies (CDC) a mis à jour sa recommandation concernant l'utilisation du vaccin à dose unique de Valneva, IXCHIQ®, pour la prévention de la maladie...

 PRESS RELEASE

Valneva to Participate in Multiple Events at the 25th World Vaccine Co...

Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ® Saint-Herblain (France), April 16, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its presence at the forthcoming 25th World Vaccine Congress, which will take place from April 21-24, 2025 at the Walter E. convention center in Washington, D.C. Under the leadership of the Company´s Chief Executive Officer, Thomas Lingelbach, a team of Valneva´s senior managers will participate in multiple events, including an impor...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch